Boxed warnings appear in the product labeling for several cardiac medications. The purpose of a boxed warning is to minimize the risk of harm. In this second part of a two-part series, we’ll review the literature that led to the boxed warnings for edoxaban (Savaysa), prasugrel (Effient) and ticagrelor (Brilinta), along with practical considerations for their use.
What’s in the Black Box? Examining the Evidence for Five Cardiac Medications? Part 1
Boxed warnings appear in the product labeling for several cardiac medications. The purpose of a BW is to minimize the risk of harm. In this two-part blog series, we’ll review the literature that led to the BWs for cilostazol (Pletal), dofetilide (Tikosyn), edoxaban (Savaysa), prasugrel (Effient) and ticagrelor (Brilinta), along with practical considerations for each. Cilostazol and dofetilide will be discussed in this first post of the series.